These results indicate that the inhibition of NF-KB p65 is a potent and safe strategy for treating gastric cancer, and thus suggest that the development of SN50-based therapeutics may be an approach for the next generation of gastric cancer treatment. This evidence concerns the gene NFKB1 and gastric cancer.